We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Collection of Tumor Tissue, Blood and Spinal Fluid From Patients With Brain or Spine Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00580463
Recruitment Status : Completed
First Posted : December 24, 2007
Last Update Posted : March 19, 2009
Rockefeller University
Information provided by:
Memorial Sloan Kettering Cancer Center

Brief Summary:
The purpose of the study is to collect samples of brain or spine tumors. Memorial Sloan-Kettering Cancer Center would then store them for use by researchers who study brain or spine cancer and try to find better ways of treating it. We will also collect blood and spinal fluid from patients with brain or spine tumors. The blood and spinal fluids are also used for research studies of cancer and its treatment.

Condition or disease
Primary or Metastatic Central Nervous System (CNS) Tumor

Detailed Description:
The main objective of the protocol is the establishment of a repository of central nervous system (CNS) tumors or metastases to the CNS and related tissues as an invaluable resource for current or future research studies of the etiology, pathogenesis and treatment of human central nervous system tumors. The database will be established through the intra-operative acquisition of brain or spine tumors as well as the collection of blood and spinal fluids from consenting CNS tumor patients.

Layout table for study information
Study Type : Observational
Actual Enrollment : 1128 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Collection of Tumor Tissue, Blood and Spinal Fluid From Patients With Brain or Spine Tumors
Study Start Date : January 2000
Actual Primary Completion Date : March 2009
Actual Study Completion Date : March 2009

Primary Outcome Measures :
  1. To establish a repository of CNS tumors or metastases to the CNS and related tissues for current or future studies. [ Time Frame: conclusion of the study ]

Biospecimen Retention:   Samples With DNA
Blood Spinal fluid

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The patient population will include adult and pediatric patients diagnosed with a primary or metastatic central nervous system tumor.

Inclusion Criteria:

  • For acquisition of intra-operative brain or spine tumor specimens, blood specimens and spinal fluid specimens, all patients who undergo surgery for resection or biopsy qualify for inclusion in this protocol.
  • If spinal fluid is not accessed as part of the operative procedure, it will not be collected.
  • All patients must be under the care of one or more members of the MSKCC CNS disease management team at the time of tissue acquisition. Patients may have been previously diagnosed and/or treated at another institution.
  • Subjects are eligible regardless of sex, age or race.
  • Parental or guardian consents will be obtained in the case of minors (less than 18 years of age)

Exclusion Criteria:

  • Patients or their guardians, in case of a minor, may choose to be excluded at any time.
  • If a patient, or guardian, decides to withdraw after some or all of the tissues have been collected, such tissues will be destroyed at their request.
  • Patients or their guardians will be counseled at the time of obtaining their consent, of the possibility of withdrawing from the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00580463

Layout table for location information
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Rockefeller University
Layout table for investigator information
Principal Investigator: Philip Gutin, MD Memorial Sloan Kettering Cancer Center
Additional Information:
Layout table for additonal information
Responsible Party: Philip Gutin, MD, Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00580463    
Other Study ID Numbers: 99-125
First Posted: December 24, 2007    Key Record Dates
Last Update Posted: March 19, 2009
Last Verified: March 2009
Keywords provided by Memorial Sloan Kettering Cancer Center:
central nervous system (CNS) tumor
tissue collection
Additional relevant MeSH terms:
Layout table for MeSH terms